Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S.

Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of patients based on the company’s investigational new drug (IND) application. This extends the company’s INJECTABL-1 trial to the treatment of metastatic colorectal cancer, lung cancer, and sarcoma patients in the USA. Read more (Official Press Release) Print

The release as fetched from its publisher. immunophotonics.com ↗